Primary Job Title Co-Founder Primary Organization 
Liquid Biotech
Gender Male
Jay F. Dorsey, MD, PhD is a co-Founder of Liquid Biotech USA. He is currently an Assistant Professor of Radiation Oncology at the University of Pennsylvania and an NIH R01-funded Physician-Scientist with an active translational research laboratory focused on circulating tumor biomarkers and development of novel anti-cancer therapies and theranostic
agents. He is a practicing Radiation Oncologist with clinical expertise in CNS malignancies and stereotactic radiosurgery. Dr. Dorsey graduated from University of Florida, Gainesville, Florida, with a B.S. degree in Chemical Engineering and received a M.S. in Chemical Engineering from the University of South Florida (USF), Tampa, FL. He completed an M.D. and Ph.D. from USF and conducted his dissertation research in cancer signal transduction at the Moffitt Cancer Center’s Molecular Oncology Program, where he was part of one of the first research groups to characterize dual Src/Bcr-Abl tyrosine kinase inhibitors as effective against Chronic Myelogenous Leukemia (CML), which ultimately led to the development of 2nd generation CML drugs such as Dasatinib and Nilotinib (effective against imatinib-resistant CML). He completed an American Board of Radiology (ABR)-sponsored research pathway residency in Radiation Oncology at the Hospital of the University of Pennsylvania and the Abramson Cancer Center and is a board-certified Radiation Oncologist. He was an ASCO Young Investigator Awardee, recipient of a Burroughs Wellcome Fund Career Award for Medical Scientists (CAMS), and an NIH-sponsored K08 Career Award. Dr. Dorsey has expertise in the areas of CTCs, nanoparticle theranostics, radiation biology, drug discovery, molecular oncology, experimental therapeutics, and early phase clinical trials.”
